International Medical News Group LLC

SHERPA: Unknown

People

  1. Lichtman
    Lichtman

Groups

  1. Department of Medicine (39)
  2. Solid Tumor Oncology Division (39)
  3. Gynecologic Medicine Service (38)
  4. Alan and Sandra Gerry Metastasis and Tumor Ecosystems Center (1)
  5. GSK Faculty (1)
  6. Melanoma and Immunotherapeutics Service (1)
Search Within
Formats
  1. Journal Article (40)
Groups
  1. Department of Medicine (39)
  2. Solid Tumor Oncology Division (39)
  3. Gynecologic Medicine Service (38)
  4. Alan and Sandra Gerry Metastasis and Tumor Ecosystems Center (1)
  5. GSK Faculty (1)
  6. Melanoma and Immunotherapeutics Service (1)
People
  1. Stuart Lichtman (38)
  2. Jedd Wolchok (1)
  3. Karyn Goodman (1)
  4. Paul Chapman (1)
Years
  1. 2015 (1)
  2. 2012 (1)
  3. 2011 (4)
  4. 2010 (4)
  5. 2007 (9)
  6. 2006 (9)

More Years

Publications
  1. The Oncology Report (40)

Results (40)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Cetuximab improves quality of life in advanced disease: Commentary
    Journal Article

    Lichtman, S. M.
    The Oncology Report (2007)

    Fulltext@MSK | Save
  • Perioperative FOLFOX4 improves survival with liver mets: Commentary
    Journal Article

    Lichtman, S. M.
    The Oncology Report (2007)

    Fulltext@MSK | Save
  • Adding bevacizumab to oxaliplatin delays progression: Commentary
    Journal Article

    Lichtman, S. M.
    The Oncology Report (2007)

    Fulltext@MSK | Save
  • Phase III trials show XELOX equivalent to FOLFOX: Commentary
    Journal Article

    Lichtman, S. M.
    The Oncology Report (2007)

    Fulltext@MSK | Save
  • Lymph node evaluations not meeting guideline standards: Commentary
    Journal Article

    Lichtman, S. M.
    The Oncology Report (2007)

    Fulltext@MSK | Save
  • Cetuximab increases response to FOLFOX4 in OPUS trial: Commentary
    Journal Article

    Lichtman, S. M.
    The Oncology Report (2007)

    Fulltext@MSK | Save
  • Chemotherapy break shortens survival in OPTIMOX2 trial: Commentary
    Journal Article

    Lichtman, S. M.
    The Oncology Report (2007)

    Fulltext@MSK | Save
  • Cetuximab cuts progression risk by 15% in CRYSTAL trial: Commentary
    Journal Article

    Lichtman, S. M.
    The Oncology Report (2007)

    Fulltext@MSK | Save
  • MOSAIC update confirms FOLFOX4 disease-free survival advantage: Commentary
    Journal Article

    Lichtman, S. M.
    The Oncology Report (2007)

    Fulltext@MSK | Save
  • Panitumumab yields promising activity in metastatic CRC - Comment
    Journal Article

    Lichtman, S. M.
    The Oncology Report (2006)

    Fulltext@MSK | Save

    • International Medical News Group LLC – authorized name for: